Radiation plus immunotherapy may make inoperable liver cancer removable

NCT ID NCT07179900

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding radiotherapy to a combination of two drugs (QL1706 and bevacizumab) can shrink liver tumors that cannot currently be removed by surgery. The goal is to make enough tumors shrink so they can be surgically removed. The study will enroll 60 adults with unresectable, non-metastatic liver cancer and compare the new combination against the drug combo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
QL1706 (Iparomlimab and Tuvonralimab Injection), bevacizumab, and radiotherapy
What this could lead to
If successful, this combination could shrink liver tumors enough to allow surgical removal, potentially improving long-term outcomes for patients with unresectable liver cancer.
What could go wrong
This is an early phase 2 trial with only 60 patients, so results may not apply broadly. The combination of drugs and radiation may cause significant side effects, and the conversion to surgery may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hebei Medical University Fourth Hospital

    RECRUITING

    Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.